Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H36N4O4.2Cl.Sn |
| Molecular Weight | 754.29 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Sn+4].CCC1=C(C)C2=CC3=NC(=CC4=C(CCC(O)=O)C(C)=C([N-]4)C=C5N=C(C=C1[N-]2)C(C)=C5CC)C(CCC(O)=O)=C3C
InChI
InChIKey=LLDZJTIZVZFNCM-UHEVNVKKSA-J
InChI=1S/C34H38N4O4.2ClH.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;;/h13-16H,7-12H2,1-6H3,(H4,35,36,37,38,39,40,41,42);2*1H;/q;;;+4/p-4/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;;;
Stannsoporfin is a mesoporphyrin derivative patented by Rockefeller University as competitive heme oxygenase (HO) inhibitor for the prevention of hyperbilirubinemia in infants at risk of developing jaundice. Parenteral administration of Stannsoporfin has been shown to suppress or moderate jaundice in a wide variety of experimental and naturally occurring forms of hyperbilirubinemia in animals and man. Stannsoporfin is rapidly cleared from the plasma in animals, in adult humans, and in newborn infants and may inhibit competitive heme oxygenase for prolonged periods. The Stannsoporfin decreases the production of carbon monoxide from heme and increases the biliary excretion of unmetabolized heme but has no effect on the metabolic disposition of preformed bilirubin.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Up-regulation of heme oxygenase-1 after infarct initiation reduces mortality, infarct size and left ventricular remodeling: experimental evidence and proof of concept. | 2014-04-05 |
|
| Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. | 2014-03 |
|
| Posttranslational mechanisms modulating the expression of the cytochrome P450 1A1 gene by methylmercury in HepG2 cells: a role of heme oxygenase-1. | 2013-06-07 |
|
| Increased heme-oxygenase 1 expression in mesenchymal stem cell-derived adipocytes decreases differentiation and lipid accumulation via upregulation of the canonical Wnt signaling cascade. | 2013-03-12 |
|
| Inhibition of heme oxygenase-1 partially reverses the arsenite-mediated decrease of CYP1A1, CYP1A2, CYP3A23, and CYP3A2 catalytic activity in isolated rat hepatocytes. | 2012-03 |
|
| Transcriptional and posttranslational mechanisms modulating the expression of the cytochrome P450 1A1 gene by lead in HepG2 cells: a role of heme oxygenase. | 2012-01-27 |
|
| In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins. | 2011-04 |
|
| Mercury modulates the CYP1A1 at transcriptional and posttranslational levels in human hepatoma HepG2 cells. | 2010-12-15 |
|
| Arsenite down-regulates cytochrome P450 1A1 at the transcriptional and posttranslational levels in human HepG2 cells. | 2010-05-15 |
|
| Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. | 2010-05 |
|
| Protein assay for heme oxygenase-1 (HO-1) induced by chemicals in HepG2 cells. | 2009-12 |
|
| Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress. | 2008-12-12 |
|
| Highly liver-specific heme oxygenase-1 induction by interleukin-11 prevents carbon tetrachloride-induced hepatotoxicity. | 2006-10 |
|
| Heme oxygenase-1 enhances renal mitochondrial transport carriers and cytochrome C oxidase activity in experimental diabetes. | 2006-06-09 |
|
| Heme oxygenase-2 deficiency contributes to diabetes-mediated increase in superoxide anion and renal dysfunction. | 2006-04 |
|
| Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. | 2005-08 |
|
| Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. | 2005-04 |
|
| Protective role of heme oxygenase-1 induction in carbon tetrachloride-induced hepatotoxicity. | 2003-09-15 |
|
| Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins. | 1994-11 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB04555MIG
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
C152424
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
DB04912
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
JJ-34
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
7752
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
100000084977
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
0KAE1U0G7Q
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
106344-20-1
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
C055421
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY | |||
|
16686132
Created by
admin on Wed Apr 02 09:33:24 GMT 2025 , Edited by admin on Wed Apr 02 09:33:24 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
